Back to search

Peptide record

TPDB05342

Temporin-Las Antibacterial Anticancer Toxicity Tumor-homing Peptides standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05342
Temporin-Las
Antibacterial Anticancer Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF TumorHoPe2.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Toxicity, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
LLRHVVKILSKYL
Physicochemical Analysis
C76H132N20O16
ANDCEQGMFPTW
L
1582.01
10.72
4
0
8
+3
0.53
0.808
194.62
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
1490
94.18
2
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
4
L
2
K
0
M
0
F
0
P
1
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 4 K: 2 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
13
C76H132N20O16
1582.01
10.72
+3
0.53
0.808
Free
L
Linear
Free
Anticancer
Temporins family
Evidence Records 14 records
Evidence 1 Activity

Activity

62.73 Inhibition ratio at 50 µg/ml
Anticancer

Target

Colorectal Cancer
SW-1116
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

59.37 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
SMMC-7721
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

56.81 Inhibition ratio at 50 µg/ml
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

55.98 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

50.85 Inhibition ratio at 50 µg/ml
Anticancer

Target

Gastric Cancer
BGC-823
Stomach

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

50.64 Inhibition ratio at 50 µg/ml
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

37.00 Inhibition ratio at 50 µg/ml
Anticancer

Target

Liver Cancer
HL7702
Liver

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 8 Activity

Activity

30.90 Inhibition ratio at 50 µg/ml
Anticancer

Target

Renal Cancer
HEK-293T
Renal

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 9 Activity

Activity

27.99 Inhibition ratio at 50 µg/ml
Anticancer

Target

Breast Cancer
MEC
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 10 Activity

Activity

37.00±0.85% Inhibition
Toxicity
50 µg/mL
Cytotoxic
37.00±0.85% Inhibition | 50 | µg/mL | target cell: Human hepatocyte cells HL-7702 (L02)

Target

Human hepatocyte cells HL-7702 (L02)

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 11 Activity

Activity

30.90±4.49% Inhibition
Toxicity
50 µg/mL
Cytotoxic
30.90±4.49% Inhibition | 50 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 12 Activity

Activity

27.99±30.32% Inhibition
Toxicity
50 µg/mL
Cytotoxic
27.99±30.32% Inhibition | 50 | µg/mL | target cell: Bovine mammary epithelial cells

Target

Bovine mammary epithelial cells

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 13 Activity

Activity

20.26±10.15% Inhibition
Toxicity
50 µg/mL
Cytotoxic
20.26±10.15% Inhibition | 50 | µg/mL | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain. | J Pept Sci | 2012
Evidence 14 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml | Cytotoxicity: Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
J Pept Sci. 2012 Jul 18(7):476-86.